Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease

Deivanai SubbiahDepartment of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, MalaysiaCorrespondence[email protected]

, MD,

Hanizasurana HashimDepartment of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia

, MS Ophthal (UKM) &

Fiona Lee Min ChewDepartment of Ophthalmology, Hospital Selayang, Batu Caves, Selangor, Malaysia

, MS Ophthal (Malaya)

References

Bitner H, Schatz P, Mizrahi-Meissonnier L, Sharon D, Resenberg T. Frequency, genotype, and clinical spectrum of Best vitelliform macular dystrophy: data from a national center in Denmark. Am J Ophthalmol. 2012;154(2):403–412. doi:10.1016/j.ajo.2012.02.036.
PubMed Web of Science ®Google Scholar
Best Disease, or Best vitelliform dystrophy. Clinical education. Amer Acad Ophthalmol. https://www.aao.org/bcscsnippetdetail.aspx?id=57a1675f-32c8-4c9e-8b3b-023929f933de Accessed October 9, 2018.
Google Scholar
Koh AV, Tan JP, Ismail S, Embong Z, Ngah NF. Choroidal neovascularization secondary to Best’s vitelliform macular dystrophy in two siblings of a Malay family. Clin Ophthalmol. 2014;8:537–542. doi:10.2147/OPTH.S55623.
PubMedGoogle Scholar
Querques G, Bocco MCA, Soubrane G, Souied EH. Intravitreal ranibizumab(Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy. Acta Ophthalmol. 2008;86(6):694–695. doi:10.1111/j.1600-0420.2007.01132.x.
PubMed Web of Science ®Google Scholar
Huang Q, Zhang Q, Fei P, et al. Ranibizumab injection as primary treatment in patients with retinopathy of prematurity. Anatomic outcomes and influencing factors. Ophthalmology. 2017;124(8):1156– 1164.doi:10.1016/j.ophtha.2017.03.018.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Recurrence of SRF Post Intravitreal Ranibizumab for Pediatric Choroidal Neovascularisation Secondary to Best Disease

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date